Phthalazine derivatives as PARP inhibitors

A compound of formula (I),

• the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein
• n is 0, 1, 2 or;
• Q is —CR3— wherein R3 is halo or C1-6alkyl;
• X is independently —N═ or —CH═, and when X is —CH═ then Y is —N═ or —NH—;
• and when X is —N═ then Y is —CH═ or —CH2;
• L1 is a direct bond or a bivalent radical selected from —C1-6alkanediyl —NH—, —NH— or —NH—C1-6alkanediyl-NH—;
• L2 is a direct bond or a bivalent radical selected from —C1-6alkanediyl-, —C2-6alkenediyl-, carbonyl or —C1-6alkanediyl- substituted with one substituent selected from hydroxy or aryl;
• R1 is hydrogen, nitro, halo or amino;
• R2 is hydrogen, C1-6alkyl or arylC1-6alkyl;
• the central
• moiety may also be bridged with an ethylene bridge;
• Z is, C1-6alkyl, C1-6alkyloxy, aryloxy, amino, cyano, arylC1-6 alkylamino or benzthiazolyl(C1-6 alkyl)amino or
• a ring system selected from
• wherein R4 and R5 are each independently selected from hydrogen, halo, C1-6 alkyl, C1-6 alkyloxy or trihalomethyl;
• aryl is phenyl, or phenyl substituted with one or two substituents each independently selected from halo, C1-6alkyl or C1-6alkyloxy.